Japan`s Inamoto fit to play in England warm-up

Johannesburg: Japan midfielder Junichi Inamoto has declared himself fit to face England on Sunday and is hoping his team mates show a bit more fight to get their World Cup preparations back on track.

The 30-year-old missed Monday`s 2-0 home loss to East Asian rivals South Korea because of a hamstring pull and watched the confidence-battering defeat from the sidelines.

"Physically, technically and mentally South Korea were at a high level and we lost out all over the pitch, so we need to try and be stronger mentally and show a bit more attitude," he told Kyodo news agency at the team`s training camp in Switzerland.

The former Arsenal and Fulham midfielder, who will be playing in his third World Cup finals in South Africa, is particularly keen to play in Sunday`s match in Austria after breaking his ankle in a previous friendly against England in 2004.

"I still have a little bit of stiffness but it`s okay," he said of his hamstring injury. "I want to play against England.”

"I have bad memories of the last time I played against England and this is a special match for me. This is another World Cup coming up for me and I need to keep up my confidence."

Inamoto was the golden boy of the Japan side that reached the last 16 as co-hosts in 2002 but on current form, the Blue Samurai will struggle to match that feat.

They begin their campaign against Cameroon on June 14 and also face Denmark and the Netherlands in Group E at the June 11-July 11 tournament.

Bureau Report

Washington: Johnson & Johnson late last month, recalled 40 widely used nonprescription products for children and infants, such as Tylenol and Motrin, after Food and Drug Administration inspectors found filthy equipment and contaminated ingredients at a Pennsylvania factory.

"This is an issue of trust," House Oversight and Government Reform Committee Chairman Edolphus Towns told a hearing held to investigate the recall. "When parents and grandparents give these medicines to their children, they want to be confident that they are not harmful."

A J&J executive told the panel that the company had not lived up to its reputation and apologized for the concern and inconvenience created by the recall.
The FDA says there have been hundreds of complaints but no children have been known to be harmed.

Investors, previously confident the problems were a minor financial concern for the diversified maker of medical and consumer products, are beginning to be cautious.
JP Morgan analysts said on Tuesday that the recall could shave J&J`s sales by $300 million this year to nearly $62.3 billion. It is also likely to dent earnings by 3 cents per share or more depending on how much it costs to fix the problems, they said.

Shares of J&J closed down 0.2 percent at $59.03 on the New York Stock Exchange on Thursday, underperforming the S&P Pharmaceuticals Sub-Industry Index which rose 1.3 percent on a day of broad stock gains.

"I think it`s beginning to be" an issue, Noble Financial Group analyst Jan Wald said of the recall. "The more serious the government is going to take it, the more serious investors are going to take it."

Lawmaker said the episode highlighted the need to give FDA more power over drugmakers. Towns said he would introduce legislation to expand FDA`s ability to order a drug recall, something that now requires a lengthy legal process and court orders if a drugmaker refuses to voluntarily issue a recall.

Since the nationwide recall was announced last month, 136 million bottles of medicine have been recalled in the fourth company recall in the last 12 months.

Bureau Report

By continuing to use the site, you agree to the use of cookies. You can find out more by clicking this link